



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_335_24

You asked:

Q1 – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2024 to the end of Mar 2024?

Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)			
Adalimumab (Biosimilars)			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept (Enbrel)			
Etanercept (Biosimilars)			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Tofacitinib			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Our response:

Under section 21 of the Act, Cwm Taf Morgannwg University Health Board is not required to provide information in response to a request if it is already reasonably accessible to you. We have answered a previous request in relation to the information you require and our responses are published via our [Disclosure Log](#) on the [Cwm Taf University Morgannwg Health Board](#) web site.

However, for ease of access please see the link to the relevant response which is referenced below:

[CTMUHB 321 24](#)